Drug Trial Radar · NCT02705105
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Feb 2016
Primary completion
Aug 22, 2018
Study completion Oct 10, 2018
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Mar 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.
Conditions
- Solid Tumor
- Cancer
- Carcinoma
- Hepatocellular Carcinoma
- HCC
Interventions
Mogamulizumab + NivolumabBiological
i.v. administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: From the first dose of study medications until 14 days after the last dose of study medication
- Number of Subjects Experiencing Dose-limiting ToxicityTime frame: From the first dose of study medications until 14 days after the last dose of study medication
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Gilbert, Arizona
Site not named
Greenbrae, California
Site not named
Los Angeles, California
Site not named
Jacksonville, Florida
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Baltimore, Maryland
Site not named
Kalamazoo, Michigan
Site not named
Piscataway, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Goldsboro, North Carolina
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.